Abstract:Coxsackievirus A10 (CVA10) has recently emerged as one of the major causative agents of hand, foot, and mouth disease. CVA10 may also cause a variety of complications. No approved vaccine or drug is currently available for CVA10. The residues of CVA10 critical for viral attachment, infectivity and in vivo pathogenicity have not been identified by experiment. Here, we report the identification of CVA10 residues important for binding to cellular receptor KREMEN1. We identified VP2 N142 as a key receptor-binding residue by screening of CVA10 mutants resistant to neutralization by soluble KREMEN1 protein. The receptor-binding residue N142 is exposed on the canyon rim but highly conserved in all naturally occurring CVA10 strains, which provides a counterexample to the canyon hypothesis. Residue N142 when mutated drastically reduced receptor-binding activity, resulting in decreased viral attachment and infection in cell culture. More importantly, residue N142 when mutated reduced viral replication in limb muscle and spinal cord of infected mice, leading to lower mortality and less severe clinical symptoms. Additionally, residue N142 when mutated could decrease viral binding affinity to anti-CVA10 polyclonal antibodies and a neutralizing monoclonal antibody and render CVA10 resistant to neutralization by the anti-CVA10 antibodies. Overall, our study highlights the essential role of VP2 residue N142 of CVA10 in the interactions with KREMEN1 receptor and neutralizing antibodies and viral virulence in mice, facilitating the understanding of the molecular mechanisms of CVA10 infection and immunity. Our study also provides important information for rational development of antibody-based treatment and vaccines against CVA10 infection. Coxsackievirus A10 (CVA10) is an emerging pathogen that causes hand, foot, and mouth disease. No approved vaccines or antiviral treatments for CVA10 infection are yet available. Here we identified VP2 N142 of CVA10 as a key residue essential for viral recognition by KREMEN1 receptor by selection of soluble receptor neutralization-resistant mutant and mutational analysis. Residue N142 when mutated could significantly reduce receptor-binding activity, viral attachment, and infection in vitro. Mouse infection experiments show that residue N142 when mutated could reduce fatality rate and severity of symptoms by decreasing viral loads in limb muscle and spinal cord. Furthermore, residue N142 when mutated could confer resistance to neutralization by anti-CVA10 neutralizing antibodies. Additionally, N142, which is exposed on the canyon rim but highly conserved in CVA10, is identified as a key receptor-binding residue, providing a counterexample to the canyon hypothesis. Overall, our findings promote a better understanding of the molecular basis of CVA10 attachment and infection and in vivo pathogenicity, and also provide useful information for rational research and development of vaccines and antibody-based treatment against CVA10 infection.

Influence of Amino Acid Substitutions in Capsid Proteins of Coxsackievirus B5 on Free Chlorine and Thermal Inactivation

Amino acid substitutions in VP2, VP1, and 2C attenuate a Coxsackievirus A16 in mice

Study of Coxsackie B viruses interactions with Coxsackie Adenovirus receptor and Decay-Accelerating Factor using Human CaCo-2 cell line

Phylodynamic and Epistatic Analysis of Coxsackievirus A24 and Its Variant

Conserved Residues Adjacent to ß-Barrel and Loop Intersection among Enterovirus VP1 Affect Viral Replication: Potential Target for Anti-Enteroviral Development

Effects of glycine 64 substitutions in RNA-dependent RNA polymerase on ribavirin sensitivity and pathogenicity of coxsackievirus A6

The introduction of mutations in the wild type coxsackievirus B3 (CVB3) IRES RNA leads to different levels of in vitro reduced replicative and translation efficiencies

Nuclease Activity and Cytotoxicity to Host Cells of Toxic Protein VapC Produced by Leptospira Species

VP2 residue N142 of coxsackievirus A10 is critical for the interaction with KREMEN1 receptor and neutralizing antibodies and the pathogenicity in mice

Differing Susceptibilities to Certain Microbicidal Chemistries among Three Representative Enveloped Viruses

Identification of a nucleotide in 5′ untranslated region contributing to virus replication and virulence of Coxsackievirus A16

Beta-Propiolactone Inactivation of Coxsackievirus A16 Induces Structural Alteration and Surface Modification of Viral Capsids

Deep mutation, insertion and deletion scanning across the Enterovirus A proteome reveals constraints shaping viral evolution

Specificity of coxsackievirus B3 interaction with human, but not murine, decay-accelerating factor: replacement of a single residue within short consensus repeat 2 prevents virus attachment

Molecular Epidemiology and Evolution of Coxsackievirus A9

Structure Elucidation of Coxsackievirus A16 in Complex with GPP3 Informs a Systematic Review of Highly Potent Capsid Binders to Enteroviruses.

Chemical inactivation of two non-enveloped viruses follows distinct molecular pathways

Crystal structures of the 3C proteases from Coxsackievirus B3 and B4

Antiviral Mechanisms of N-Phenyl Benzamides on Coxsackie Virus A9

Chaetocin significantly inhibits coxsackievirus B3 replication in vitro

Comparative Pathogenicity of Coxsackievirus A16 Circulating and Noncirculating Strains in Vitro and in a Neonatal Mouse Model.